Genesis Therapeutics is pairing proven drug developers with the industry's most advanced small molecule discovery platform, to accelerate and optimize the development of new medicines.
Location: United States, California, Burlingame
Employees: 11-50
Total raised: $256.1M
Founded date: 2019
Investors 7
| Date | Name | Website |
| - | Harpoon Ve... | harpoon.vc |
| 20.06.2021 | Open Field... | ofcap.com |
| - | a16z | a16z.com/ |
| 23.12.2020 | Felicis Ve... | felicis.co... |
| - | Radical Ve... | radical.vc |
| 18.06.2020 | JAZZ Ventu... | jazzvp.com |
| - | Propagator... | propagator... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 22.08.2023 | Series B | $200M | T. Rowe Pr... |
| 03.12.2020 | Series A | $52M | - |
| 21.11.2019 | Seed | $4.1M | - |
Mentions in press and media 22
| Date | Title | Description |
| 14.11.2024 | Genesis Therapeutics: Pioneering AI in Drug Discovery with NVentures' Backing | In the fast-paced world of biotechnology, innovation is the lifeblood. Genesis Therapeutics, a trailblazer in artificial intelligence (AI) for drug development, is making waves. The company recently secured a significant equity investment f... |
| 14.11.2024 | Genesis Therapeutics Receives Equity Investment From NVIDIA | Genesis Therapeutics, a Burlingame, CA-based company providing artificial intelligence (AI) technologies to create medicines for patients, announced an equity investment from NVIDIA’s NVentures. The amount of the deal was not disclosed. The... |
| 13.11.2024 | NVentures Invests in Genesis Therapeutics’ AI Platform for Drug Development | What You Should Know: – Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, announced today a further equity investment from NVentures, NVIDIA’s venture capital... |
| 11.09.2024 | Gilead Sciences and Genesis Therapeutics Partner on AI-Driven Drug Discovery | What You Should Know: – Gilead Sciences, a global biopharmaceutical company, and Genesis Therapeutics, an AI-focused biotechnology firm, have announced a strategic collaboration to discover and develop innovative small molecule therapies. –... |
| 12.10.2023 | Bytes to Bites part three – Wellness wired: Leveraging AI to digitize nutrition and health | Editor’s Note: Eva Everloo is senior investment analyst and Dr. Anđela Martinović is scientific analyst at agrifood tech investor PeakBridge. The views expressed in this guest commentary are the authors’ own and do not necessarily reflect t... |
| 22.08.2023 | USA-based Genesis Therapeutics closes oversubscribed Series B round at USD 200 million | California, USA-based company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients with severe diseases, Genesis Therapeutics, closed its oversubscribed Series B round at USD 200 million. The co... |
| 21.08.2023 | Genesis Therapeutics Completes $200M Series B | BURLINGAME, CA, Genesis Therapeutics, harnessing AI to create medicines for patients with severe diseases, announced a $200 million Oversubscribed Series B funding round. >> Click here for more funding data on Genesis Therapeutics ... |
| 21.08.2023 | A16z-Backed AI Biotech Startup Genesis Therapeutics Raises $200M | 10 Shares Email Facebook Twitter LinkedIn Artificial intelligence and biotech are two of the sectors that have been able to buck the current sluggish pace of venture capital spending. So it’s not surprising a startup at the intersection of ... |
| 21.08.2023 | Genesis Therapeutics Closes $200M Series B Funding | Genesis Therapeutics, a Burlingame, CA-based artificial intelligence (AI) tech company which specializes in medicines for patients with severe diseases, raised $200M in Series B funding. The round was led by co-led by a U.S.-based life-scie... |
| 10.01.2022 | New Year, New Fund, New Opportunities in Bio + Health | 2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both upstarts and tradit... |
Show more